Toxoplasma gondii protease inhibitor-1 (TgPI-1) is a novel vaccine candidate against toxoplasmosis

dc.creatorCuppari, Anahi Fernandez
dc.creatorSanchez, Vanesa
dc.creatorLedesma, Bibiana A
dc.creatorFrank, Fernanda M.
dc.creatorGoldman, Alejandra
dc.creatorAngel, Sergio O.
dc.creatorMartín, Valentina
dc.date2021-01-26T15:42:24Z
dc.date2021-01-26T15:42:24Z
dc.date2008-09-15
dc.date.accessioned2023-08-29T20:09:10Z
dc.date.available2023-08-29T20:09:10Z
dc.identifier0264-410X
dc.identifierhttp://sgc.anlis.gob.ar/handle/123456789/2253
dc.identifier10.1016/j.vaccine.2008.07.031
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8520538
dc.descriptionFil: Cuppari, Anahi Fernandez. Laboratorio de Inmunología, Centro de Salud y Medio Ambiente, E.C.y T., Universidad de Gral. San Martín, Provincia de Buenos Aires; Argentina.
dc.descriptionFil: Sanchez, Vanesa. Laboratorio de Inmunología, Centro de Salud y Medio Ambiente, E.C.y T., Universidad de Gral. San Martín, Provincia de Buenos Aires; Argentina.
dc.descriptionFil: Ledesma, Bibiana. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Parasitología; Argentina.
dc.descriptionFil: Frank, Fernanda M. Departamento de Microbiología, Parasitología e Inmunología, Facultad de Medicina, and Facultad de Farmacia y Bioquímica, IDEHU, CONICET Universidad de Buenos Aires, Buenos Aires; Argentina
dc.descriptionFil: Goldman, Alejandra. Laboratorio de Inmunología, Centro de Salud y Medio Ambiente, E.C.y T., Universidad de Gral. San Martín, Provincia de Buenos Aires, Argentina.
dc.descriptionFil: Angel, Sergio O. Laboratorio de Parasitología Molecular, IIB-INTECH, CONICET-UNSAM, Chascomús, Provincia de Buenos Aires, Argentina.
dc.descriptionFil: Martin, Valentina. Laboratorio de Inmunología, Centro de Salud y Medio Ambiente, E.C.y T., Universidad de Gral. San Martín, Provincia de Buenos Aires; Argentina.
dc.descriptionThe Toxoplasma gondii serin protease inhibitor-1 (TgPI-1) is a dense granule antigen that showed to specifically inhibit trypsin, chymotrypsin and neutrophil elastase, suggesting a possible modulatory role during the parasite invasion process and on the development of the innate immune response. To study the immune-protective value of TgPI-1, C3H/HeN mice were immunized with a recombinant form of the antigen rTgPI-1 combined with alum. All immunized mice produced specific anti-rTgPI-1 immunoglobulins, with high IgG antibody titers and a mixed IgG(1)/IgG(2a) response, with predominance of IgG(1) production. The cellular immune response was associated with the production of IFN-gamma and IL-10 cytokines. Vaccinated mice displayed significant protection against an oral challenge either after a lethal infection with Me49 cysts (90% survival vs. 50%) and also after a non-lethal infection (58% reduction in brain parasite load) compared to the non-vaccinated control group. In conclusion, rTgPI-1 elicits a strong specific immune response providing partial protection against both T. gondii acute and chronic infection, so it would be a good candidate in a vaccine against toxoplasmosis, which could be combined with other relevant parasite antigens.
dc.languageen
dc.publisherElsevier
dc.relationVaccine
dc.rightsnone
dc.sourceVaccine 2008; 26(39):5040-5.
dc.subjectToxoplasma
dc.subjectToxoplasmosis
dc.titleToxoplasma gondii protease inhibitor-1 (TgPI-1) is a novel vaccine candidate against toxoplasmosis
dc.typeArtículo


Este ítem pertenece a la siguiente institución